Effect of clomipramine on monoamine metabolites in the cerebrospinal fluid of behaviorally normal dogs

Canadian Journal of Veterinary Research

Volumn 64, Issue 2, 2000, Pages 123-129

  Hewson, Caroline J ^a,b   Luescher, U Andrew ^a,c   Parent, Joane M ^a   Ball, Ronald O ^a,d  

^a UNIVERSITY OF GUELPH   (Canada)

^b 2 Wenderton Farm Cottages ^*  (United Kingdom)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DOPAMINE; NORADRENALIN; SEROTONIN;

ARTICLE; CEREBROSPINAL FLUID; COMPULSION; DOG; DRUG EFFECT; DRUG EFFICACY; MONOAMINE METABOLISM; NEUROCHEMISTRY; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; COMPULSIVE BEHAVIOR; DOG DISEASES; DOGS; DOPAMINE; MALE; NOREPINEPHRINE; SEROTONIN;

CANIS FAMILIARIS;

EID: 0033942077     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hewson CJ, Luescher UA, Parent JM, Conlon PD, Ball RO. Efficacy of clomipramine in the treatment of canine compulsive disorder: a randomized, placebo-controlled, double-blind clinical trial. J Am Vet Med Assoc 1998;213:1760-1766.
2. Hewson CJ, Luescher UA. Compulsive disorder in dogs. In: Voith VL, Borchelt PL, eds. Readings in Companion Animal Behavior. Trenton, New Jersey: Veterinary Learning Systems, 1996:153-158.
3. Cabib S. Neurobiological basis of stereotypies. In: Lawrence A, Rushen J, eds. Stereotypic Animal Behaviour: Fundamentals and Application to Welfare. Wallingford, England: CAB International, 1993:119-145.
4. Hall H, Ogren S-O. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 1981;70:393-407.
5. Westerink B, Lejeune B, Korf J, Van Praag H. On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur J Pharmacol 1977;42: 179-190.
6. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. Depression and mania. In: Hardman JG, Goodman AG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996:431-445.
7. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476.
8. Benfield DP, Harries CM, Luscombe DK. Some pharmacological aspects of desmethylclomipramine. Postgrad Med J 1980;56, (1 Suppl):13-18.
9. Thomas PC, Jones RB. The effects of clomipramine and desmethylclomipramine on the in vitro uptake of radiolabelled 5-HT and noradrenaline into rat brain cortical slices. J Pharmacy Pharmacol 1977;29:562-563.
10. Commissiong JW. Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem Pharmacol 1985;34:1127-1131.
11. Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 1985;37:333-364.
12. DeMet EM, Halaris AE. Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids. Biochem Pharmacol 1979;28:3043-3050.
13. Träskman L, Äsberg M, Bertilsson L, et al. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther 1979;26:600-610.
14. Äsberg M, Ringberger V-A, Sjoqvist F, Thorén P, Träskman L, Tuck JR. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with clomipramine. Clin Pharmacol Ther 1977;21:201-207.
15. Thorén P, Åsberg M, Bertilsson L, Mellström B, Sjöqvist F, Träskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980;37: 1289-1294.
16. Altemus M, Swedo S, Leonard H. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive compulsive disorder with clomipramine. Arch Gen Psychiatry 1994;51: 794-803.
17. Insel TR, Winslow JT. Neurobiology of obsessive-compulsive behaviors. In: Jenike MA, Baer L, Minichello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. Chicago: Year Book Medical Publishers, 1991:118-131.
18. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970;126:983-987.
19. Faull KF, Brachas JD, Foutz AS, Dement WC, Holman RB. Monoamine metabolite concentrations in the cerebrospinal fluid of normal and narcoleptic dogs. Brain Res 1982;242:137-143.
20. Vaughn DM, Coleman E, Simpson ST, Satjawatcharaphong C. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid. Am J Vet Res 1988;49:1302-1306.
21. Rapoport JL, Ryland DH, Kriete M. Drug treatment of canine acral lick. An animal model of obsessive compulsive disorder. Arch Gen Psychiatry 1992;49:517-521.
22. Marder AR. Psychotropic drugs and behavioral therapy. In: Marder AR, Voith V, eds. Advances in Companion Animal Behavior. Veterinary Clinics of North America: Small Animal Practice. Philadelphia: WB Saunders, 1991:329-342.
23. Bourgoin S, Ternaux JP, Boireau A, Hery F, Hamon M. Effects of halothane and nitrous oxide anaesthesia on 5-HT turn-over in the rat brain. Naunyn Schmiedeburgs Arch Pharmacol 1975;288:109-121.
24. Hewson CJ, Conlon PD, Luescher UA, Ball RO. The pharmacokinetics of clomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. J Vet Pharmacol Ther 1998;21:214-222.
25. Langlais PJ, Bird ED, McEntee WJ. Stability of monoamine metabolites in human cerebrospinal fluid. Ann Neurol 1982;12: 48-51.
26. Scheinin M, Chang W-H, Kirk KL, Linnoila M. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydrox-yindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high performance liquid chromatography using electrochemical detection. Anal Biochem 1983;131:246-253.
27. Godbillon J, Gauron S. Determination of clomipramine or imipramine and their mono-demethylated metabolites in human blood or plasma by high-performance liquid chromatography. J Chromatogr 1981;204:303-311.
28. Sioufi A, Pommier F, Dubois JF. Simultaneous determination of clomipramine and its N-demethylated metabolite in human whole blood by capillary gas chromatography. J Chromatogr 1988;428:71-80.
29. Senn S. Crossover Trials in Clinical Research. Chichester, England: John Wiley and Sons, 1993:226-238.
30. Streiner DL. An introduction to multivariate statistics. Can J Psychiatry 1993;38:9-13.
31. Bertilsson L, Asberg M. Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: methodological aspects. In: Usdin E, ed. Frontiers in Biochemical and Pharmacological Research in Depression. New York: Raven Press, 1984:27-34.
32. Kobayashi K, Imazu Y, Kawabata M, Shomori T. Effect of long-term storage on monoamine metabolite levels in human cerebrospinal fluid. Acta Med Okayama 1987;41:179-181.
33. Linnoila M, Ninan PT, Scheinin M, et al. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients. Arch Gen Psychiatry 1983;40: 1290-1294.
34. Moir ATB, Ashcroft GW, Crawford TBB, Eccleston D, Guldberg HC. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain Res 1970;93:357-368.
35. Eccleston D, Ashcroft GW, Moir ATB, Parker-Rhodes A, Lutz W, O'Mahoney DP. A comparison of 5-hydroxyindoles in various regions of dog brain and cerebrospinal fluid. J Neurochem 1968;15:947-957.
36. Mefford IN, Foutz AS, Noyce N, Jurik SM, Handen C, Dement WC, Barchas JD. Distribution of norepinephrine, epinephrine, dopamine, serotonin, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindole-3-acetic acid in dog brain. Brain Res 1982;236:339-349.
37. Guldberg HC, Ashcroft GW, Crawford TBB. Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid. Life Sci 1966;5:1571-1575.
38. Friedman E, Cooper TB. Pharmacokinetics of chlorimipramine and its demethylated metabolites in blood and brain regions of rats treated acutely and chronically with chlorimipramine. J Pharmacol Exp Ther 1983;225:387-390.
39. Fujita K, Kobayashi A, Suzuki S, Nakazawa K. Changes of serotonin and catecholamines are related to pharmacokinetic alterations of clomipramine in rat brain. Eur J Pharmacol 1991; 204:227-233.
40. Adell A, Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. Naunyn Schmiedeburgs Arch Pharmacol 1991;343:237-244.